Dear visitors, members and future members,
CARS welcomes you to our new home. You are welcome to share your ideas, developments and latest results of your research with your colleagues and other professionals with interest in radiopharmaceutical sciences.
The new website is a friendly environment where everyone is welcomed. Join CARS, access the member reserved area, and you will find more.
We hope that you enjoy your journey and that you will join us to enrich the community of radiopharmaceutical scientists.
Canadian Association of
Radiopharmaceutical Scientists (CARS)
- Hold scientific meetings at which members may discuss their work; such meetings need not necessarily be held on a regular basis;
- Monitor and where necessary, respond to government actions which affect either the routine preparation of radiopharmaceuticals or radiopharmaceutical research and development;
- Monitor and respond to actions of any third party which have an effect on professional practice of the members of the Association.
- Facilitate open discussions between community members
Who We Are
CARS is a professional association established with the objective of the communication of radiopharmaceutical and scientific knowledge.
Stakeholders of CARS include public at large, scientists and those with professional interest in any aspect of radiopharmaceutical sciences. CARS is facilitating an open communication between all categories of stakeholders.
Our members have access to the latest resources for professional development in radiopharmaceutical sciences.
You have access to regulatory information, latest communications in the field and updates regarding the market trends and developments in the field
CARS is welcoming you to share your ideas, news, events and topics related to radiopharmaceutical sciences on our new forum.
The space is designed to strengthen our community and to encourage open communication about your progress, challenges or new ideas.
CARS aim to provide information for educational and information only purposes.
- January 8, 2021
The purpose of this notice is to recommend modified wording for the indications and clinical uses of fludeoxyglucose (F-18 FDG) products in their product monographs. The recommended wording aims to bring the indications and clinical uses for F-18 FDG up-to-date and harmonize F-18 FDG product monographs in this regard. You can access the document here: […]Read More
- October 7, 2020
Dear colleagues, The Calgary Radiopharmaceutical Centre (CRC) is addressing the shortage of Mebrofenin kits. CRC announces the availability for distribution of Stannous DISIDA Kits used in hepatobiliary imaging. For information regarding orders send your request to CalgaryRadiopharm@ahs.ca, For details please contact: Ingrid Koslowsky, Director Calgary Radiopharmaceutical Centre Foothills Medical Centre 1433-29 St W Calgary, Alberta, Canada […]Read More
- June 17, 2020
On March 30, 2020, Health Canada published a Notice communicating that the use of the Regulatory Enrolment Process (REP) will be mandatory as of October 1, 2020, for pharmaceutical, biologic and radiopharmaceutical drugs for human use as well as disinfectants, pursuant to Part C, Division 1 and Division 8 of the Food and Drug Regulations. […]Read More